论文部分内容阅读
多数骨髓增生异常综合征(MDS)患者用粒细胞集落刺激因子(G-CSF)能增加粒细胞数,但对Hb和血小板数作用有限。红细胞生成素(Epo)约可改善20％MDS患者的贫血。在体外,G-CSF和Epo对正常和骨髓增生异常的红细胞生成有协同作用,作者对22例MDS(6例贫血稳定,16例需输血)进行Ⅱ期临床试验。先单给G-CSF6周,然后在以后的12周与Epo联合治疗,调整G-CSF剂量(0.3,1.0
Most myelodysplastic syndromes (MDS) patients with granulocyte colony stimulating factor (G-CSF) can increase the number of granulocytes, but the role of Hb and platelets limited. Epo (erythropoietin) improves anemia in about 20% of MDS patients. In vitro, G-CSF and Epo have synergistic effects on normal and myeloproliferative erythropoiesis. The authors conducted phase II clinical trials of 22 patients with MDS (6 anemic stable and 16 required transfusion). G-CSF alone was given for 6 weeks before treatment with Epo for the next 12 weeks to adjust G-CSF dose (0.3, 1.0